Wed, May 7, 1:22 PM (15 days ago)
**Avadel Pharmaceuticals PLC (AVDL) Q1 2025 Financial Summary** **Financial Performance:** - **Revenue:** Q1 2025 revenue was $52.5 million, up 93.2% from $27.2 million in Q1 2024, driven by LUMRYZ sales. - **Gross Profit:** Increased by 82.9% to $46.9 million, with a gross margin of 89%. - **Operating Expenses:** Total operating expenses decreased by 3.4% to $49.9 million. Selling, general, and administrative expenses decreased by 6.3% to $45.6 million, while research and development expenses increased by 41.9% to $4.4 million due to clinical trials. - **Net Loss:** Net loss narrowed by 82% to $4.9 million, with a diluted net loss per share of $0.05, compared to $0.30 in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $8.2 million, a 72.3% improvement from $29.7 million in Q1 2024. Cash and marketable securities decreased by $7.3 million to $66.5 million. **Business Highlights:** - **LUMRYZ:** Approved for pediatric narcolepsy patients, with 2,800 patients on LUMRYZ as of March 31, 2025. - **REVITALYZ Trial:** Pivotal trial for Idiopathic Hypersomnia initiated, with the first patient dosed. - **Litigation:** Ongoing patent disputes with Jazz Pharmaceuticals, with recent court rulings favoring Avadel. **Future Outlook:** - **Uncertainties:** Potential impacts from tariffs, inflation, and rising interest rates. - **Liquidity:** Existing cash, cash equivalents, and marketable securities, along with anticipated LUMRYZ sales, are expected to meet operating and capital requirements for the next 12 months. - **Strategic Partnerships:** Potential partnerships for commercialization, manufacturing, and distribution of LUMRYZ.